Trial site
Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn gGmbH
Paderborn, 33098, GermanyNot linked to an institution yet
- 23running trials
- 5closed trials
The trials here
What the 28 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 210 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Recruiting13 trials
- Active, not recruiting10 trials
- Completed5 trials
- Lead sponsor
- University Of Cologne4 trials
- Christian Buske2 trials
- Universitaetsklinikum Heidelberg AöR2 trials
- University of Heidelberg Medical Center2 trials
- AbbVie1 trial
- and 17 more
Running trials
Recruiting
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
PREFer
NCT06916416· Phase 2· University Of Cologne· Source
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307· Phase 2· Universität Münster· Source
Recruiting
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
2023-510294-34-00· Phase 3· University Of Cologne· Source
Not yet recruiting
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477· Phase 3· Dominik Paul Modest· Source
Recruiting
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
NCT05099471· Phase 2· Christian Buske· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Active, not recruiting
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
NCT04837859· Phase 2· University Of Cologne· Source
Recruiting
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Active, not recruiting
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· Phase 2· Goethe University· Source
Recruiting
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
NCT05820841· Phase 3· Universität des Saarlandes· Source
Active, not recruiting
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
NCT05676203· Phase 3· Jena University Hospital· Source
Recruiting
Venetoclax in combination with Ibrutinib and Rituximab or conventional
chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients
with Mantle Cell Lymphoma.
2022-501808-96-00· Phase 2· Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR· Source
Recruiting
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
NCT05665140· Phase 2/3· University Hopsital Schleswig Holstein Campus Lübeck· Source
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436· Phase 2· AbbVie· Source
Active, not recruiting
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
NCT04263480· Phase 2· Christian Buske· Source
Active, not recruiting
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092· Phase 3· Incyte Corporation· Source
Active, not recruiting
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients
NCT04246684· Phase 3· Prof. Dr. med. Claus Rödel· Source
Active, not recruiting
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure
NCT04495088· Phase 3· Heidelberg University· Source
Recruiting
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
NCT04385290· Phase 1/2· Technische Universität Dresden· Source
Active, not recruiting
Frontline Asciminib Combination in Chronic Phase CML
NCT03906292· Phase 2· University of Jena· Source
Active, not recruiting
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731· Phase 3· University of Heidelberg Medical Center· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error